Association Between Salivary Soluble RANKL, OPG Concentration and Mandibular Resorption to Clinically Predict Severe Residual Ridge Resorption Risk

Background. Affecting all individuals, residual ridge resorption (RRR) is a prevalent, progressive condition developing post tooth loss, often remaining silent until denture instability occurs. The molecular mechanisms and predictive bone biomarkers for severe RRR in edentulous individuals are poorly understood.

Object.This study aimed to investigate:

1. The association between salivary soluble Receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG) concentration and the extent of mandibular resorption
2. Propose a way to clinically predict severe RRR risk. Methods.This cross-sectional study, conducted at the Faculty of Dentistry, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam (November 2021 to April 2024), enrolled 140 systemically healthy, edentulous adults (mean age 69.2 ± 8 years). Participants were stratified into atrophic (n=70) and non-atrophic (n=70) groups based on mandibular height. Demographic data (age, sex), edentulous duration, and denture history were recorded. Unstimulated whole saliva samples (5 mL) were collected, and salivary RANKL and OPG concentrations were quantified by ELISA.

Study Overview

• Status: Completed
• Conditions: Edentulism in Lower Jaw

Detailed Description

This cross-sectional study was approved by the Ethical Committee Board of the University of Medicine and Pharmacy in Ho Chi Minh City (UMP) (No.488/HĐĐĐ-ĐHYD), recruited participants between November 2021 and April 2024. All participants provided informed and written consent before clinical examinations and saliva. A convenience sampling method was employed. Of the 254 potential edentulous participants, 140 participants were included in the study.

Participant grouping: Participants underwent panoramic radiography to assess mandibular ridge height. They were classified into two groups. Atrophic groups have mandibular ridge heights less than 25 mm anteriorly and less than 16 mm posteriorly. In the non-atrophic group, mandibular ridge height is ≥ 25 mm anteriorly and ≥ 16 mm posteriorly.

Clinical factors: The participant's age, sex, duration of edentulism, and past complete denture experience were collected by the patient or patient's relative interview.

To obtain unstimulated whole saliva from each participants, approximately 5 ml was collected. Before the collection, all participants were instructed to refrain from eating and drinking for at least 30 minutes. Between 7:00 and 8:00 a.m., the collection was conducted through expectoration into sterile polypropylene tubes. Immediately after collection, the samples were placed in a cool box containing an ice pack and then hand-delivered to the Center for Molecular Biomedicine at UMP, Ho Chi Minh City, Vietnam.

RANKL and OPG salivary levels were measured using enzyme-linked immunosorbent assay Data analysis, including the relationship between RANKL, OPG and other variables, and the development of a predictive nomogram for high-risk bone resorption, was performed using R language version 3.4.0.

• Study Type: Observational
• Enrollment (Actual): 140

Contacts and Locations

Study Locations

• Vietnam
  • Ho Chi Minh, Vietnam
    • Faculty of Dentistry, University of Medicine and Pharmacy Ho Chi Minh City, Viet Nam

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Edentulous participants seeking oral care and treatment at the Faculty of Dentistry Clinic of the University of Medicine and Pharmacy Ho Chi Minh City from November 2021 to April 2024.

Description

Inclusion Criteria:

• complete edentulism for more than 3 years
• age > 35 years old
• no history of bone augmentation or mandibular defects

Exclusion Criteria:

• systemic diseases known to affect bone metabolism or immune function
• a history of malignancy
• salivary gland disease
• using antibiotics or immunosuppressant medications within 3 months

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Atrophic mandibular ridge
Non-Atrophic mandibular ridge

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The concentration level of nuclear factor-κB ligand (RANKL)	It is measured using enzyme-linked immunosorbent assay (ELISA) kits (CSBE05125h, Cusabio, China ) mixing with the participant saliva	within 6 months after sample collection
The concentration level of osteoprotegerin (OPG)	It is measured using enzyme-linked immunosorbent assay (ELISA) kits (CEHTNFRSF11B, Invitrogen, Massachusetts, USA ) mixing with the participant saliva	within 6 months after sample collection

Collaborators and Investigators

• Sponsor: Nguyen Thu Thuy

Study record dates

Study Major Dates

• Study Start (Actual): November 30, 2021
• Primary Completion (Actual): April 1, 2024
• Study Completion (Actual): April 1, 2024

Study Registration Dates

• First Submitted: January 29, 2025
• First Submitted That Met QC Criteria: January 29, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 29, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: 488/HĐĐĐ-DHYD

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Privacy concern

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No